ClinVar Miner

Submissions for variant NM_030777.4(SLC2A10):c.504C>A (p.Phe168Leu)

dbSNP: rs540023880
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000199476 SCV000250737 uncertain significance not provided 2018-11-26 criteria provided, single submitter clinical testing The F168L variant of uncertain significance in the SLC2A10 gene has not been published in association with ATS to our knowledge. This variant is observed in 26/246090 (0.01%) alleles from individuals of multiple ethnic backgrounds, including one homozygous individual, in large population cohorts indicating this may be a rare benign variant (Lek et al., 2016). The F168L variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Nevertheless, in-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or rare benign.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001192939 SCV001361408 uncertain significance not specified 2019-10-08 criteria provided, single submitter clinical testing Variant summary: SLC2A10 c.504C>A (p.Phe168Leu) results in a non-conservative amino acid change located in the Major facilitator superfamily domain (IPR020846) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0001 in 251300 control chromosomes in the gnomAD database, including 1 homozygotes. This frequency is not significantly higher than expected for a pathogenic variant in SLC2A10 causing Aortopathy (0.0001 vs 0.0016), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.504C>A in individuals affected with Aortopathy and no experimental evidence demonstrating its impact on protein function have been reported. A ClinVar submission (evaluation after 2014) cites the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
Invitae RCV002054312 SCV002493867 likely benign Arterial tortuosity syndrome 2022-11-12 criteria provided, single submitter clinical testing
Ambry Genetics RCV002336533 SCV002641858 uncertain significance Familial thoracic aortic aneurysm and aortic dissection 2021-08-02 criteria provided, single submitter clinical testing The p.F168L variant (also known as c.504C>A), located in coding exon 2 of the SLC2A10 gene, results from a C to A substitution at nucleotide position 504. The phenylalanine at codon 168 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species; however, leucine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.